VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Akebia Therapeutics, Inc. (AKBA) Total Return Calculator with Dividends Reinvested

Akebia Therapeutics, Inc.

Popular:

The total return for Akebia Therapeutics, Inc. (AKBA) stock is -52.03% over the past 12 months. So far it's down 23.87% this year. The 5-year total return is -62.18%, meaning $10,000 invested in AKBA stock 5 years ago would be worth $3,782 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in AKBA 1 year ago, it would be worth $4,504 today — you'd have lost $5,496.

With Dividends Reinvested$4,504-54.96%

Price Only (No DRIP)$4,504-54.96%

Period2025-05-08 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in AKBA

1Y$4,797-$5,203 (-52.0%)-52.0% CAGR

3Y$11,132+$1,132 (+11.3%)3.6% CAGR

5Y$3,782-$6,218 (-62.2%)-17.7% CAGR

10Y$1,427-$8,573 (-85.7%)-17.7% CAGR

15Y$442-$9,558 (-95.6%)-18.8% CAGR

20Y$442-$9,558 (-95.6%)-14.4% CAGR

30Y$442-$9,558 (-95.6%)-9.9% CAGR

Akebia Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading AKBA total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-23.87%	—	-23.87%	—	$7,613
1Y	-52.03%	-52.03%	-52.03%	—	$4,797
3Y	+11.32%	3.64%	+11.32%	—	$11,132
5Y	-62.18%	-17.67%	-62.18%	—	$3,782
10Y	-85.73%	-17.69%	-85.73%	—	$1,427
15Y	-95.58%	-18.77%	-95.58%	—	$442
20Y	-95.58%	-14.44%	-95.58%	—	$442
30Y	-95.58%	-9.87%	-95.58%	—	$442

Risk & Highlights

Best Year+99.04%2023

Worst Year-76.45%2022

Max Drawdown-70.57%2025-07-23 → 2026-02-18

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-15.48%	-15.48%	—	+0.41%	-15.9pp
2025	-15.26%	-15.26%	—	+16.64%	-31.9pp
2024	+49.61%	+49.61%	—	+24.00%	+25.6pp
2023	+99.04%	+99.04%	—	+24.81%	+74.2pp
2022	-76.45%	-76.45%	—	-19.95%	-56.5pp

AKBA underperformed the S&P 500 by 82.40pp over the past year (-52.03% vs +30.37%).

Loading summary...

AKBA Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
AKBAAkebia Therapeutics, Inc.	$317M	-14.5%	-23.9%	-52.0%	—	+11.3%	-62.2%	-85.7%
FOLDAmicus Therapeutics, Inc.	$4.5B	+0.1%	+1.5%	+137.9%	—	+19.0%	+48.6%	+119.2%
PTGXProtagonist Therapeutics, Inc.	$6.4B	-4.7%	+13.4%	+129.4%	—	+296.5%	+238.8%	+744.9%
CYCNCyclerion Therapeutics, Inc.	$14M	-9.5%	+135.1%	-8.2%	—	-46.8%	-94.3%	-98.7%
ANIPANI Pharmaceuticals, Inc.	$1.8B	+5.6%	+7.0%	+18.5%	—	+97.1%	+117.4%	+84.7%
HALOHalozyme Therapeutics, Inc.	$7.7B	+2.5%	-7.3%	-7.1%	—	+115.3%	+37.0%	+570.7%
PRTAProthena Corporation plc	$567M	+1.6%	+14.5%	+44.4%	—	-86.3%	-57.2%	-73.0%
FXNCFirst National Corporation	$253M	+1.1%	+14.6%	+46.9%	+3.3pp	+110.8%	+68.7%	+241.1%
GSKGSK plc	$101.6B	-9.6%	+2.7%	+40.7%	+4.8pp	+50.4%	+53.6%	+63.0%
AMGNAmgen Inc.	$177.6B	-3.2%	+1.2%	+22.8%	+3.5pp	+51.9%	+46.2%	+156.4%
RPRXRoyalty Pharma plc	$21.5B	+7.1%	+29.8%	+56.0%	+2.7pp	+48.5%	+32.4%	+22.9%

Compare:AKBA vs FOLD AKBA vs PTGX AKBA vs CYCN AKBA vs FOLD vs PTGX

About AKBA Dividend Returns

Akebia Therapeutics, Inc. (AKBA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of AKBA over the past year?

Akebia Therapeutics, Inc. (AKBA) delivered a return of -52.03% over the past year. Since AKBA does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in AKBA be worth today?

A $10,000 investment in Akebia Therapeutics, Inc. one year ago would be worth $4,797 today, representing a loss of $5,203.

Q3Does AKBA pay dividends?

Akebia Therapeutics, Inc. (AKBA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For AKBA, the total return equals the price-only return.

Q4Did AKBA beat the S&P 500?

No, Akebia Therapeutics, Inc. (AKBA) underperformed the S&P 500 by 82.40 percentage points over the past year. AKBA delivered a total return of -52.03%, compared to the S&P 500's 30.37%. This means a passive S&P 500 index fund outperformed AKBA by 82.40pp during this period.

Q5What is AKBA's worst drawdown?

Akebia Therapeutics, Inc. (AKBA) experienced a maximum drawdown of -70.57% over the past year, declining from its peak on 2025-07-23 to its trough on 2026-02-18. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is AKBA's long-term total return over 10, 20, or 30 years?

Here are Akebia Therapeutics, Inc. (AKBA)'s long-term returns with dividends reinvested. Over 10 years, the total return is -85.7% (-17.7% CAGR) — $10,000 would have grown to $1,427. Over 20 years: -95.6% total return (-14.4% CAGR) — $10,000 → $442. Over 30 years: -95.6% total return (-9.9% CAGR) — $10,000 → $442. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was AKBA's best and worst year?

Akebia Therapeutics, Inc.'s best calendar year was 2023 with a total return of 99.0%. Its worst year was 2022 with a total return of -76.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 175.5 percentage points.